Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Johnson and Johnson
AstraZeneca
McKesson
Boehringer Ingelheim

Last Updated: February 3, 2023

CLINICAL TRIALS PROFILE FOR EXPAREL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


505(b)(2) Clinical Trials for Exparel

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT01349140 ↗ EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks Completed Pacira Pharmaceuticals, Inc Phase 1 2012-02-01 EXPARELâ„¢, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duration formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied in a fixed volume adjacent to the femoral nerve.
New Formulation NCT01349140 ↗ EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks Completed University of California, San Diego Phase 1 2012-02-01 EXPARELâ„¢, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duration formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied in a fixed volume adjacent to the femoral nerve.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Exparel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00485433 ↗ Dose-ranging Study for Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair Completed Pacira Pharmaceuticals, Inc Phase 2 2007-06-01 The purpose of this study is to evaluate three dose levels of SKY0402 compared with 105 mg of bupivacaine HCl.
NCT00485693 ↗ Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty Completed Pacira Pharmaceuticals, Inc Phase 2 2007-06-01 Dose-ranging study for prolonged postoperative analgesia in subjects undergoing total knee arthroplasty
NCT00529126 ↗ Phase 2 Dose-Ranging Study of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy Completed Pacira Pharmaceuticals, Inc Phase 2 2007-09-01 Phase 2 study to evaluate three dose levels of SKY0402 compared with 75 mg of bupivacaine HCl.
NCT00813111 ↗ Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation Terminated Pacira Pharmaceuticals, Inc Phase 3 2008-11-01 The purpose of this study is to provide a more effective postoperative method of pain control for patients undergoing cosmetic sub-muscular breast augmentation. Appropriate postoperative pain management contributes to faster patient mobilization, shortened hospital stays, and reduced healthcare costs.
NCT00890682 ↗ Study of Postoperative Analgesia in Bunionectomy Completed Pacira Pharmaceuticals, Inc Phase 3 2009-04-01 After undergoing bunion surgery, patients are given a pain medicine injection that may last for up to several days or a placebo. Their pain and pain medicine use is then monitored.
NCT00890721 ↗ Study of Pain Control in Hemorrhoidectomy Completed Pacira Pharmaceuticals, Inc Phase 3 2009-05-01 Patients will get an injection of either SKY0402 or placebo during hemorrhoid surgery, and their pain and pain medicine use will be monitored.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Exparel

Condition Name

Condition Name for Exparel
Intervention Trials
Pain, Postoperative 41
Pain 31
Postoperative Pain 25
Opioid Use 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Exparel
Intervention Trials
Pain, Postoperative 91
Osteoarthritis 17
Rotator Cuff Injuries 11
Osteoarthritis, Knee 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Exparel

Trials by Country

Trials by Country for Exparel
Location Trials
United States 350
Denmark 4
Belgium 3
Poland 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Exparel
Location Trials
Ohio 34
Texas 34
New York 29
California 26
Florida 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Exparel

Clinical Trial Phase

Clinical Trial Phase for Exparel
Clinical Trial Phase Trials
Phase 4 148
Phase 3 33
Phase 2/Phase 3 6
[disabled in preview] 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Exparel
Clinical Trial Phase Trials
Completed 110
Recruiting 43
Terminated 36
[disabled in preview] 64
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Exparel

Sponsor Name

Sponsor Name for Exparel
Sponsor Trials
Pacira Pharmaceuticals, Inc 61
Mayo Clinic 10
The Cleveland Clinic 7
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Exparel
Sponsor Trials
Other 250
Industry 67
U.S. Fed 7
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
AstraZeneca
Harvard Business School
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.